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Pulmonary alveolar microlithiasis (PAM) is a rare genetic lung disease characterized by calcifi-
cations within the alveoli. Mutations in the SLC34A2 gene, which encodes a type IIb sodium-
phosphate cotransporter, are responsible for this disease, leading to intra-alveolar accumula-
tion of phosphate that favors the formation of microliths. The hallmark of this disorder is
clinical-radiological dissociation, with typical imaging findings that correlate well with specific
pathological findings. The long-term prognosis is poor and no treatment has been discovered to
date. The aim of this review is to describe the main pathological, clinical, and imaging aspects
of PAM, ranging from its genetic basis to treatment.
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Pulmonary alveolar microlithiasis (PAM) is a rare autosomal-
recessive disorder characterized by intra-alveolar accu-
mulation of spherical calcified concretions (called calci-
ferites, calcospherites, or microliths), in the absence of any
known calcium metabolism disorder. Most patients are
asymptomatic at the time of diagnosis and the disease is
usually detected incidentally during routine examinations,
although the diagnosis can be made during the investigation
of family history in an individual with alveolar
microlithiasis.1,2
PAM may affect people of any age, ranging from early
childhood to advanced age. However, affected individuals
usually become symptomatic in the third orfourth decade
of life. The occurrence may be sporadic or familial; about
one-third of cases are hereditary, with autosomal-recessive
inheritance.1,2
A “sandstorm” appearance is the typical radiographic
presentation of this disease.3 Given the striking dissociation
between the radiological appearance and clinical presen-
tation of PAM, the diagnosis is sometimes based on radio-
logical findings, particularly when the disease has affected
another member of the patient’s family.2
PAM has been diagnosed in patients in various stages of
life, and the disease has a long and progressive course
resulting in the deterioration of lung function.1The
pathology of PAM has been attributed to a mutation in the
type IIb sodium-phosphate cotransporter (SLC34A2) gene,
which is involved in phosphate homeostasis in various
organs, including the lungs, that induces excessive phos-
phate accumulation that may later act as a nidus for
microlith formation.4 This review describes the main clin-
ical, pathological, and imaging aspects of PAM.Epidemiology
PAM has been found on all continents, with no particular
geographic or racial distribution. It is more prevalent inEurope, followed by Asia, notably Asia Minor, with most
cases found in countries such as Turkey and Italy.2
The age of PAM onset is difficult to establish because the
disease is generally diagnosed incidentally on a chest
radiograph requested for other reasons. Although PAM has
been described in all age groups, including one case report
in an 8-month-old infant,5 the mean age at diagnosis is 35
years among cases reported in the literature. No significant
gender predominance has been observed.1,2,6,7Genetic aspects
Familial cases of PAM occur at reported frequencies ranging
from 36% to 61%, indicating the importance of genetic
factors in the genesis of the disease.2 PAM has been re-
ported to occur among siblings and cousins in a horizontal
pattern,6,8,9 and less frequently between parents and
children in a vertical pattern of familial inheritance.10,11
Several authors independently identified the gene
responsible for PAM. These studies found that homozygous
mutations in the gene of solute carrier family 34 (sodium-
phosphate), member 2 (SLC34A2) are significantly related
to PAM, as this gene encodes a type IIb sodium-dependent
phosphate transporter (NaPi-IIb).4,8,12e15 In a genetic
analysis of a family with consanguineous marriage, Dogan
et al16 noted that three children diagnosed with PAM had
a homozygous mutation in the SLC34A2 gene and that their
parents, who were carriers of the disease, had a heterozy-
gous mutation in the same gene. These findings suggest that
impaired activity of the SLC34A2 gene may be responsible
for familial PAM. Thus, evidence supports the hypothesis
that this disease is hereditary and related to the pattern of
autosomal-recessive inheritance with a high penetrance.12
These mutations occur very rarely; the frequency of
a chromosome with a mutant gene in the general pop-
ulation is less than 0.008.1
The SLC34A2 gene is located on the short arm of chro-
mosome 4 (4p15). It has 13 exons, the first one noncoding,
and encodes a 2280-nt mRNA and a 690eamino acid
protein. The homozygous mutations described may occur in
Pulmonary alveolar microlithiasis 3different ways, such as by frameshifts, chain terminations,
and amino acid substitutions, among others.13 These
mutations can determine the production of a defective
protein or abolish gene expression,4,17 resulting in the loss
of function of the encoding protein.4,13
The SLC34A2 gene encodes a membrane protein that is
expressed primarily in the apical portions of alveolar type II
cells18 and is the most common phosphate carrier in the
lungs.12It has eight predicted transmembrane domains;
proteins lacking five of these domains are likely to lose
normal function.4Figure 1 Photomicrograph of a section of resected lung
tissue showing a concentrically laminated microlith filling the
alveolar space (original magnification,  100; hematoxylin and
eosin stain).Pathogenesis
Transepithelial transport of a variety of solutes across the
alveolar epithelium maintains the composition of alveolar
fluid. Type II alveolar cells have many important functions
in the lung, including the regulation of surfactant metab-
olism, ion transport, and alveolar repair. Several types of
epithelial transport occur in type II cells, including carriage
as sodium-dependent glucose and the transport of amino
acids, protons, and sodium along epithelial sodium chan-
nels. These and other means of transepithelial transport
may provide the substrate required for the synthesis of
pulmonary surfactant in type II cells.12
Type II cells produce pulmonary surfactant, of which
phospholipids are essential constituents. Outdated surfac-
tant is taken up by type II cells for recycling and degrada-
tion and by alveolar macrophages for degradation.
Degraded phospholipids release phosphate that should be
cleared from the alveolar space.19 The wild-type IIb
sodium-phosphate cotransporter transports phosphate in
the presence of sodium, whereas mutants do not. These
proteins cotransport sodium and phosphate into the cells
with a stoichiometry of 3Naþ1:1HPO4
2, forming NaH2PO4
and thus producing inward current. The wild-type IIb
sodium-phosphate cotransporter elicited inward current
with the addition of NaH2PO4, whereas mutants did not.
4
Therefore, the inability of type II alveolar cells to clean
phosphorus ions from the alveolar space may lead to
microlith formation in the extracellular fluid.12,19
The type IIb sodium-phosphate cotransporter is a protein
expressed primarily in the lungs and mammary glands, and
less frequently in various other tissues of epithelial origin,
such as the small intestine, kidney, pancreas, ovaries, liver,
testes, placenta, and prostate. In most cases, the lungs are
the only affected organs.20 Calcium deposits have been
found in other organs in patients with PAM, including the
pleura, kidneys,21 seminal vesicles,22 urethra and gall-
bladder.23 Aortic valve calcification and arteriosclerosis
have also been described.24
Three sodium-phosphate cotransporters have been
identified in mammals (types IeIII). Types I and II are
expressed primarily in the kidneys, liver, and small intes-
tine, whereas type III is distributed ubiquitously, including
in the lungs. The type II NaPi cotransporter can be sub-
divided into types IIa and IIb. The first is expressed mainly
in proximal tubules, and no evidence has been found for its
expression in the lungs. PAM is characterized by a loss of
type IIb sodium-phosphate cotransporter function.25A low dietary phosphate intake increases the expression
of type IIa NaPi cotransporter in the kidney and small
intestine, but results in no change in the amount of IIb
protein in the lungs. This finding suggests that type IIb is not
regulated directly or indirectly by dietary phosphate
content via 1,25 dihydroxyvitamin D3.18Pathology
The pathological findings of the PAM may be confined to
certain areas or show diffuse distribution through the
lungs.26 Lung biopsy and autopsy specimens demonstrate
characteristic intra-alveolar lamellar microliths.26,27
Calcium deposits in the alveoli begin in the lower lobes
and spread over a period of years throughout the lungs,
progressing to the middle thirds and then to the upper
portions.1
Microliths associated with PAM are ovoid or round and
have diameters of 0.01e2.8 mm.1 X-ray energy-dispersive
spectroscopy of the microliths yielded a phosphorus:cal-
cium ratio of 1:2, consistent with calcium phosphate and
calcium hydroxyapatite or carboxyapatite.27 Deposits of
iron, zinc, aluminum, silica, and magnesium are also
encountered frequently.1
Histologically, the microliths are periodic acid-Schiffe-
positive26 and consist of calcareous concentric lamellae
around a central nucleus with an amorphous or granular
aspect (Fig. 1). This appearance is distinct from those of
metastatic and dystrophic calcifications, which are located
in the interstitial or vascular compartments.28
In the early stages of PAM, the interlobular septa are
intact and the gas exchange is normal. When the concre-
tions are small, spaces may exist between the alveolar
walls and microliths. These microliths gradually grow within
the alveoli to fill the entire alveolar space and contact the
walls, exerting pressure and causing damage that leads to
the replacement of the walls by fibrous tissue.1,27
On macroscopic examination, lungs affected by PAM
show reduced elasticity and can weigh up to 5 kg in cases of
Figure 2 Chest radiograph of a 25-year-old male patient with
pulmonary alveolar microlithiasis, showing diffuse opacifica-
tion in both lungs with a dense micronodular (‘‘sandstorm’’)
appearance.
4 F.A. Ferreira Francisco et al.diffuse distribution. The outer surfaces of the lungs are
granular and irregular due to protrusions of microliths by
visceral pleura. Greatly increased parenchymal resistance
is also apparent.1 On gross examination, apical blebs and
bullae may be present in the anterior portions and lung
apices.26
Clinical manifestations
The hallmark of this disorder is clinical-radiological disso-
ciation, meaning that clinicians will find a paucity of
symptoms in contrast to imaging findings.29 At diagnosis,
most patients are asymptomatic and changes in the lung
parenchyma are found incidentally. In more serious cases,
cyanosis and clubbing are the first detected signs. The most
common symptom is dyspnea, followed by dry cough, chest
pain, sporadic hemoptysis, and asthenia.1,2,12,26 Pneumo-
thoraces have also been reported.3 Direct stimulation by
microliths is believed to induce unmyelinated C fibers,
which are found in the bronchial tree and lung parenchyma,
to release tachykinins, which have potent inflammatory
effects and activate other receptors, thereby causing
cough.1,30
In the general clinical course of PAM, microliths probably
begin forming early in childhood, but clinical symptoms arise
much later.13 In the early stages of the disease, when lung
involvement is limited, pulmonary function tests are normal.
In later stages, as the disease progresses, the microliths
occupy a large number of alveoli and the lungs become
hardened, causing deterioration of mechanical ventilatory
disorders as well as perfusion and ultimately resulting in
hypoxemia, increased arterial carbon dioxide levels,
pulmonary hypertension, and cor pulmonale.1,2,12,15,31
Routine blood test findings, including serum calcium
concentration and hepatic, renal, and parathyroid func-
tions, remain normal in patients with PAM. Marked eleva-
tions in the serum concentrations of surfactant proteins A
and D have been recently reported; these proteins are also
elevated in patients with pulmonary alveolar proteinosis
and pulmonary fibrosis. These increases in serum levels may
be explained by the histological characteristics of PAM, one
of which is diffuse fibrosis in the parenchyma that increases
permeability, leading to elevated levels of these two
proteins in the blood. These levels increase further with the
deterioration of pulmonary function. They may therefore
serve as markers to monitor disease activity and
progression.32
Extrapulmonary manifestations
Extrapulmonary calcifications related to mutations in the
SLC34A2 gene include medullary nephrocalcinosis, neph-
rolithiasis,21 cholelithiasis,23 calcification of the lumbar
sympathetic chain, and testicular involvement.33 Calcifi-
cations in the seminal vesicles22 and epididymal and peri-
urethral calcifications causing obstructive azoospermia
have also been described.34 Cardiac complications, such as
aortic and mitral valve24 and pericardiac calcifications,
have been reported.35,36
Comorbidities associated with PAM include pectus
excavatum,37 hypertrophic pulmonary osteoarthropathy,38milk-alkali syndrome,39 diaphyseal aclasia,40 autosomal-
recessive Waardenburg anophthalmia syndrome,41 and
lymphocytic interstitial pneumonitis.42 A case of PAM after
varicella zoster infection has been reported in a patient
with antiphospholipid syndrome and discoid lupus eryth-
ematosus.43 Extrapulmonary calcifications may vary
according to the penetrance of the mutation.12Imaging findings
Chest radiography
Plain chest radiographs of patients with PAM usually reveal
diffuse, scattered, bilateral areas of micronodular calcifi-
cations, producing a "sandstorm” appearance (Fig. 2) that
first involves the inferior portions and then the middle and
upper portions of the lungs.1 The distribution of calcified
nodules can also be explained by the increased blood
supply to these areas.44 The lung bases show increased
density due to thicker lung tissue and increased surface
densities.7 The calcifications may be so dense that may
obliterate the cardiac borders, diaphragm, and costo-
phrenic or cardiophrenic sinuses.6,45
Other radiographic findings include small apical bullae
and a black pleural line, which appears as an area of linear
hyperlucency caused by small, thin-walled subpleural
cysts.3,7 This line, which some authors have described as
the “black pleura” sign, is visible on chest radiographs
between the calcified parenchyma and the ribs or
Pulmonary alveolar microlithiasis 5mediastinum.3,7 Radiographs of most patients with PAM do
not show the black pleural line, and subpleural cysts can be
detected more clearly by high-resolution computed
tomography (HRCT), as described below.45Figure 3 High-resolution computed tomographic images of
a 31-year-old female patient with pulmonary alveolar micro-
lithiasis. Images obtained at the levels of the superior (A) and
inferior (B) lobes with an intermediary window show hyper-
dense consolidations in both lungs caused by the confluence of
calcified nodules.High-resolution computed tomography
On HRCT, the most common findings are diffuse ground-
glass attenuation and subpleural linear calcifications.
Tomographic alterations are predominant in the inferior
and posterior portions of the lungs.6,7,41,45e47 Additionally,
the medial aspects of the lungs appear to be more heavily
involved than the lateral aspects.45 Ground-glass opacities,
probably due to small calculi in the air space,6 are the most
common finding in children and in patients with early-stage
PAM.41 Subpleural linear calcifications due to the accumu-
lation of intra-alveolar calculi in the peripheries of
secondary pulmonary lobules demarcate the pleural
surface and appear as pseudo-pleural calcifications.7,46
Other alterations found on HRCT images are small
parenchymal nodules, nodular fissures, subpleural nodules,
calcifications along the interlobular septa that sometimes
show a crazy-paving pattern, dense consolidations, and
subpleural cysts. HRCT can also highlight areas of bullous
emphysema in the apices. The crazy-paving pattern is
defined as areas of ground-glass opacity with thickening of
interposed interlobular septa, which occurs due to the
accumulation of calculi in the peripheries of secondary
pulmonary lobules. This pattern can also be observed in
mediastinal window images because calcification is present
along the interlobular septa. The literature contains no
report of any other disease with a similar tomographic
manifestation; these HRCT findings are thus considered to
be very specific and even pathognomonic of PAM.6,47
The small nodules seen on HRCT images correspond to
the typical “sandstorm” appearance of dense micronodules
(<1 mm) on plain chest radiographs and are very thin, well
defined, and diffusely spread throughout the parenchyma,
making the lungs homogeneously hypotransparent. The
calcium density of the nodules is often impossible to define
on HRCT images, probably due to their small dimensions.
When they converge to form parenchymal consolidation,
density can be better characterized and is often greater
than that of the soft tissues.3,6 These consolidations
predominantly occur along the heart borders in the lower
posterior regions of the lungs and tend to be symmetrical
(Fig. 3). Dense consolidations containing interposed air
bronchograms can be present, especially in the lower
posterior regions.6,7,45,48
Studies of PAM using HRCT imaging have frequently
mentioned the presence of subpleural cysts with diameters
of 5e10 mm that may represent early lung fibrosis.45 These
cysts correspond to the “black pleura” sign described in the
radiography section above. Using HRCT, Hoshino et al46
suggested that this radiographic sign corresponded to the
fat-dense layer between the ribs and calcified parenchyma.
However, other authors were not able to detect fat density
in any of the corresponding sites and the structure of these
black pleural lines remains unclear because they are too
thin to clearly visualize.45Areas of bullous emphysema may also be found on the
anterior margins and apices of the lungs, and an associated
pneumothorax may be seen.49
The findings of PAM on plain chest radiography and CT
are so characteristic that more diagnostic investigations are
usually unnecessary, especially in patients whose families
contain another member with PAM.2
Magnetic resonance imaging
On magnetic resonance imaging (MRI), the calcific lesions
usually show hypointensity or a signal void on T1- and T2-
weighted images. Hoshino et al46 described a case in which
MRI showed numerous, likely diffuse, microliths in the
lower zones of the lungs as an increased signal intensity on
T1-weighted images. Henkelman et al50 found that partic-
ulate calcium with a microscopically visible high crystal
surface area can reduce T1 relaxation times, producing
a predominant T1 effect. Thus, the surface area of these
small calcific nodules may be very large, leading to
increased signal intensity on T1-weighted images.
6 F.A. Ferreira Francisco et al.Interstitial fibrosis and thickened alveolar walls are often
seen in advanced stages of PAM, but these changes show
higher signal intensity on T2- than on T1-weighted
images.46,50
Nuclear medicine
In patients with PAM, bone scintigraphy scanning agents,
such as technetium (Tc)-99m methylene diphosphonate,
should be taken up in the lungs due to chemisorption on the
surfaces of calcium salts, the principal components of
microliths.51 Tc-99melabeled diphosphonate compounds
have a natural affinity for calcification foci at the soft-
tissue level and may detect early pulmonary calcification
in PAM.28
In a case report, Gu¨nay et al52 observed low 18F-fluo-
rodeoxyglucose (FDG) uptake in the calcifications of PAM
and lower FDG accumulation in the lung parenchyma
without micronodular opacities. They thus suggested
that combined positron emission tomography/computed
tomography using 18F-FDG (18F-FDG-PET/CT) revealed low
maximal standardized uptake values in patients with PAM
due the normal levels of inflammatory markers. Ito et al53
reported a case in which high FDG uptake was observed in
lung lesions showing sparing calcifications on CT, with no
evidence of severe inflammation, whereas low uptake was
observed in radiodense areas. Given the death of this
patient within 1 month of the examination producing these
findings, they postulated that high FDG uptake may beTable 1 Pulmonary function parameters in patients with
pulmonary alveolar microlithiasis.
Respiratory function tests
FVC (L) Normal or low
FEV1 (L) Normal
FEV1/FVC (%) Normal or high
TLC (L) Low
RV (L) Normal
RV/TLC (%) Normal
DLCO (mL CO/min/mmHg) Normal or low
VT(L) Normal or low
VE (L/min) Normal
VO2 (mL/kg/min) Normal
QVA/QT (%) Normal or high
VD/VT (%) High
Arterial blood gases
pH Normal or high
PaO2 (mmHg) Normal or low
PaCO2 (mmHg) Normal or low
SaO2 (%) Normal or low
(Aea) PO2 (mmHg) High
FVC, forced vital capacity; FEV1, forced expiratory volume in
1 s; TLC, total lung capacity; RV, residual volume; DLCO, lung
diffusing capacity; VT, tidal volume; VE, minute ventilation
volume; VO2, O2 consumption; QVA/QT, venous admixture-like
effect; VD, physiological dead space; pH, hydrogenionic
potential; PAO2, alveolar O2tension; PaCO2, arterial CO2
tension; SaO2, arterial O2 saturation; Aea, alveolar arterial
gradient.a poor prognosis predictor for PAM. Therefore, FDG accu-
mulation observed on PET/CT is not helpful for differential
diagnosis, but may be useful for the evaluation of inflam-
mation or the prediction of a patient’s prognosis.52,53
Pulmonary function tests
Pulmonary function tests, arterial blood gases, ventilation
perfusion relationships, and O2 diffusing capacity are
normal in the initial stages of PAM. As the disease prog-
resses, pulmonary function tests reveal typical features of
a restrictive defect with reduced forced vital capacity
(FVC) and elevated forced expiratory volume in 1 s/FVC.
Reduced total lung capacity and tidal volume (VT) have also
been described (Table 1).12,26,46,54,55
Arterial blood gas studies over a period of years can
show resting hypoxemia that worsens with exercise, vari-
able PaCO2 values, and reduced O2diffusing capacity. The
alveolar arterial O2 gradient, venous admixture-like effect,
and ratio of physiological dead space to VT can be greater
than normal in patients with PAM (Table 1). These findings
suggest the presence of alveoli that are hypoventilated in
relation to pulmonary capillary blood flow, leading to
reduced O2 tension in the mixed arterial blood.
12,26,46,54,55
The paucity of studies investigating lung function in
patients with PAM and the lack of disease staging and
padronization limit its characterization.
The anatomic basis for these disturbances in lung func-
tion islikely multifactorial, including septal fibrosis and
thickening and the physical presence of space-occupying
microliths that may adhere to the alveolar membrane,
resulting in the uneven distribution of inspired gas.55
Clinical course
PAM has been described in different age groups ranging
from children to seniors, but it is usually diagnosed around
the age of 40 years.2 Although the disease course is often
protracted, patients may be asymptomatic for years before
respiratory insufficiency becomes manifest,1,12 usually in
the third or fourth decade of life.
The slow and progressive evolution of the disease may
be responsible for the heterogeneity of symptoms. In some
cases, the disease remains static; in others, it progresses
over time to lung fibrosis, respiratory failure, and cor pul-
monale accompanied by dyspnea and deterioration in
pulmonary function test results demonstrating progressive
worsening of the restrictive pattern and gas exchange.2,56
Increased turnover of alveolar epithelial cells due to
inflammation or smoking may accelerate the onset and
development of symptoms in patients with reduced
SLC34A2 gene activity. Thus, smokers have more severe
clinical phenotypes than non-smokers.13
Long-term survival in patients with PAM remains uncer-
tain, likely due to variability in the clinical course; diag-
nostic parameters may not reflect the onset of the disease.
PAM normally progresses within 10e20 years,1 and most
cases have been followed for up to 10 years after initial
diagnosis; however follow-up periods of >40 years have
been reported in a few cases.2,57 Death typically occurs
10e15 years after diagnosis,26 at a mean age within the fifth
Pulmonary alveolar microlithiasis 7decade of life, from respiratory failure due to pulmonary
hypertension and cor pulmonale.12 Chronic irritation of
alveolar walls by microliths has been speculated to cause
pulmonary fibrosis and destruction of alveolar wall capil-
laries. Thus, decreased pulmonary capillary beds associated
with pulmonary fibrosis are responsible for marked pulmo-
nary hypertension and cor pulmonale. PAM thus causes slow
and progressive impairment of lung architecture, resulting
in hypoxemia and a restrictive pattern.56,57 Thus, the
pathologic process involves parenchymal and vascular
tissues.55 For these reasons, the long-term prognosis is poor
in patients with PAM, even in those first diagnosed during the
asymptomatic phase in childhood.
Diagnosis
PAM is usually diagnosed on the basis of a typical radio-
logical pattern, namely a very fine, sand-like micro-
nodulation of calcific density diffusely involving both lungs,
with basal predominance. Many authors argue that this
pattern precludes the need for a lung biopsy in most
cases.1,6,51 However, histological examination shows intra-
alveolar microliths in the alveolar spaces and can reveal
an increase in chronic inflammatory cells that may induce
interstitial fibrosis. Microliths may also be seen in the
interstitium.31 They are purple-brown with concentric
layering and resemble psammoma bodies. A pericentral
crescentic halo is frequently apparent. Single and multiple
intracellular microliths can be engulfed by uninuclear or
multinuclear alveolar macrophages.58 Microliths can some-
times be found in sputum or bronchoalveolar lavage, which
can contain alveolar macrophages with or without carbon
particles.58
Calcifications within the lung can result from a number
of systemic and pulmonary conditions, and the differential
diagnosis is complex, including sarcoidosis, pneumoconi-
osis, pulmonary hemosiderosis, amyloidosis, miliary tuber-
culosis, histoplasmosis, calcifications after viral
pneumonia, and metastatic pulmonary calcifications asso-
ciated with chronic renal failure.45,59,60
After PAM is diagnosed in a given patient, family
members should be screened by chest radiography, and
parents should be counseled that future children are also at
risk of developing the disease.44
Treatment
To date, no treatment has been proven to effectively
prevent the progression of PAM. The disease may progress
with chronic alveolar calcification causing interstitial
inflammation, and fibrosis leading to decreased lung
volumes and, eventually, right heart failure.58
Systemic steroids and bronchoalveolar lavage are inef-
fective for the treatment of PAM.12 Currently, the only
effective therapy is lung transplantation, especially when it
is performed before the disease progresses to an advanced
stage.61
Disodium etidronate, a diphosphonate, has been used to
treat PAM with mixed results. It acts by inhibiting the
formation of new pulmonary calcium-phosphate crystalli-
zation and resolving previously formed calcifications, asobserved in other diseases.62 Some reports have shown
little or no benefit of this therapy,63,64 whereas other
studies have demonstrated an improvement in lung func-
tions and radiological changes.62,65
Lung transplantation has been beneficial in patients with
severe respiratory failure and right heart failure who
require supplemental oxygen therapy.61 To maximize the
chances of a successful outcome, such patients should be
referred before the development of severe right ventricular
dysfunction. Patients who undergone lung transplantation
have shown an increase in right ventricular ejection frac-
tion and regression of right ventricular hypertrophy.49
However, few published cases have reported lung trans-
plantation in patients with PAM, and most transplantations
have been bilateral. Survival after lung transplant and the
risk of PAM recurrence are unknown. To date, the longest
survival for a patient with PAM treated with lung trans-
plantation is 15 years without recurrence. As PAM requires
years to become clinically manifest, further follow-up
studies are required to understand the rates of survival
and risk of recurrence.66
Conclusion
PAM is a genetic lung disease with an autosomal-recessive
trait caused by mutations of the SLC34A2 gene. Microlith
formation is the result of phosphate-chelating calcium in the
extracellular fluid. The disease shows an important clinical-
radiological dissociation. Most patients are asymptomatic
and changes in the lung parenchyma are incidental findings,
but other cases exhibit more severe symptoms at diagnosis.
Because characteristic chest CT findings correlate well
with specific pathological findings, the diagnosis of PAM can
be made on the basis of the typical radiological pattern.
The long-term prognosis is poor due to progressive deteri-
orations in pulmonary function, respiratory failure and, cor
pulmonale. No effective treatment has been established;
thus, lung transplantation is currently the only effective
therapy.
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